NCT00366899View on ClinicalTrials.gov

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

605

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Vaccines, Pneumococcal
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.

BIOLOGICAL

7 valent pneumococcal conjugate vaccine

Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.

Trial Locations (13)

16132

Genoa

20122

Milan

28100

Novara

40138

Bologna

50132

Florence

74100

Taranto

80122

Napoli

80139

Napoli

90100

Palermo

97100

Ragusa

00100

Rome

00165

Rome

07100

Sassari

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00366899 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants | Biotech Hunter | Biotech Hunter